连续布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病的一线：全面概述。

IF 2.7 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2025-07-07 DOI:10.1016/j.hoc.2025.05.006

Seema Ali Bhat, Jennifer A Woyach

{"title":"连续布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病的一线：全面概述。","authors":"Seema Ali Bhat, Jennifer A Woyach","doi":"10.1016/j.hoc.2025.05.006","DOIUrl":null,"url":null,"abstract":"Continuous treatment with Bruton's tyrosine kinase (BTK) inhibitors is well established for chronic lymphocytic leukemia in the frontline setting. Long-term data shows near-normal life expectancy for patients who are treated with ibrutinib. Second-generation BTK inhibitors have improved tolerability compared to ibrutinib and continue to show long-term durable remissions. Time-limited treatments with venetoclax combined with obinutuzumab or a BTK inhibitor demonstrate durable disease control as well. However, achieving superior and sustained long-term outcomes compared to continuous BTK inhibitor treatment remains challenging, particularly in high-risk genomic subgroups.","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.\",\"authors\":\"Seema Ali Bhat, Jennifer A Woyach\",\"doi\":\"10.1016/j.hoc.2025.05.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Continuous treatment with Bruton's tyrosine kinase (BTK) inhibitors is well established for chronic lymphocytic leukemia in the frontline setting. Long-term data shows near-normal life expectancy for patients who are treated with ibrutinib. Second-generation BTK inhibitors have improved tolerability compared to ibrutinib and continue to show long-term durable remissions. Time-limited treatments with venetoclax combined with obinutuzumab or a BTK inhibitor demonstrate durable disease control as well. However, achieving superior and sustained long-term outcomes compared to continuous BTK inhibitor treatment remains challenging, particularly in high-risk genomic subgroups.\",\"PeriodicalId\":55060,\"journal\":{\"name\":\"Hematology-Oncology Clinics of North America\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology-Oncology Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hoc.2025.05.006\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hoc.2025.05.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

持续使用布鲁顿酪氨酸激酶（BTK）抑制剂治疗慢性淋巴细胞白血病在一线已经得到了很好的证实。长期数据显示，接受伊鲁替尼治疗的患者预期寿命接近正常。与依鲁替尼相比，第二代BTK抑制剂具有更好的耐受性，并继续显示出长期持久的缓解。venetoclax联合obinutuzumab或BTK抑制剂的限时治疗也显示出持久的疾病控制。然而，与持续的BTK抑制剂治疗相比，实现优越和持续的长期结果仍然具有挑战性，特别是在高风险基因组亚群中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.

Continuous treatment with Bruton's tyrosine kinase (BTK) inhibitors is well established for chronic lymphocytic leukemia in the frontline setting. Long-term data shows near-normal life expectancy for patients who are treated with ibrutinib. Second-generation BTK inhibitors have improved tolerability compared to ibrutinib and continue to show long-term durable remissions. Time-limited treatments with venetoclax combined with obinutuzumab or a BTK inhibitor demonstrate durable disease control as well. However, achieving superior and sustained long-term outcomes compared to continuous BTK inhibitor treatment remains challenging, particularly in high-risk genomic subgroups.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.